Demonstrates ART26.12's Differentiated Profile as a Promising Pain Treatment Ahead of Planned Multiple Ascending Dose Study This Year

Phase 1 SAD Study Exhibited Excellent Safety with Zero Adverse Events Attributed to ART26.12

SOLANA BEACH, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical‑stage pharmaceutical company focused on modulating lipid‑signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced the publication of a peer‑reviewed article titled "Evaluating fatty acid-binding protein 5 (FABP5) as a therapeutic target for pain management" in the European Journal of Pain, an internationally recognized journal in pain research.

The article discusses preclinical evidence showing that FABP5 inhibition produced analgesic effects across multiple pain models, including visceral, inflammatory, neuropathic, and joint pain. The publication also highlights evidence that FABP5 inhibition may influence several established pain-related pathways while reducing pro-inflammatory mediators, supporting its potential as a differentiated, non-opioid therapeutic approach.

These findings are supported by a broader body of evidence – specifically for ART26.12 – from seven prior preclinical studies in diabetic neuropathy, osteoarthritis, cancer bone pain, and peripheral neuropathy caused by chemotherapy. ART26.12 demonstrated consistent analgesic activity across each model and validated FABP5 as a novel lipid-signaling target for pain treatment.